pharmaceutical

A recent Institute for Clinical and Economic Review (ICER) “Report on Unsupported Price Increases,” concluded that: “Among the top drugs with price increases in 2019…ICER determined that seven of 10 lacked adequate new evidence to demonstrate a substantial clinical benefit that was not yet previously known.”  The impression left by the report is that drug companies arbitrarily raise prices without good reason.  As with so many ICER products, the study is misleading and demonstrates a profound lack of business acumen.

Study: Requiring Drug Companies to Disclose Price Methodologies, Other Proprietary Information Would Discourage Drug Development, Lead to Higher Long-Term Healthcare Costs Promoting competition, looking more closely at healthcare price opacity would be more effective ways to limit cost inflation Read coverage of...